Treatment of Acquired Sideroblastic Anemias

Hematol Oncol Clin North Am. 2020 Apr;34(2):401-420. doi: 10.1016/j.hoc.2019.11.002. Epub 2020 Jan 21.

Abstract

Sideroblastic anemias are a heterogeneous group of disorders unified by the presence of abnormal erythroid precursors with perinuclear mitochondrial iron deposition in the bone marrow. Based on etiology, they are classified into clonal and nonclonal. Clonal sideroblastic anemias refer to myeloid neoplasms with ring sideroblasts (RS) and frequently have somatic perturbations in the SF3B1 gene. Anemia is a major cause of morbidity in patients, and restoration of effective erythropoiesis is a major treatment goal. Morbidity includes transfusion and disease-related complications. This article focuses on treatment of acquired sideroblastic anemias and highlights areas of future investigation.

Keywords: MDS; MDS-RS; RS; Ring sideroblast; SF3B1.

Publication types

  • Review

MeSH terms

  • Anemia, Sideroblastic / diagnosis
  • Anemia, Sideroblastic / etiology
  • Anemia, Sideroblastic / therapy*
  • Biomarkers
  • Clonal Evolution
  • Combined Modality Therapy
  • Disease Management
  • Disease Progression
  • Disease Susceptibility
  • Erythroid Cells / drug effects
  • Erythroid Cells / metabolism
  • Erythroid Cells / pathology
  • Erythropoiesis / drug effects
  • Hematinics / pharmacology
  • Hematinics / therapeutic use
  • Humans
  • Hyperplasia
  • Immunologic Factors / immunology
  • Immunologic Factors / therapeutic use
  • Mutation
  • Myelodysplastic Syndromes / diagnosis
  • Myelodysplastic Syndromes / etiology
  • Myelodysplastic Syndromes / therapy
  • Treatment Outcome

Substances

  • Biomarkers
  • Hematinics
  • Immunologic Factors